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Pulmonary hypertension is a common occurrence in advanced COPD, but its effects on exercise
capacity remain undetermined. Exercise testing and an echocardiographic examination were
performed in 29 patients with advanced stable COPD. Mean pulmonary artery pressure (mPAP)
was calculated from the acceleration time of pulmonary flow. Exercise capacity was evaluated
by the distance walked in 6 min (6MWD) and by an incremental cardiopulmonary exercise test
(CPET). The patients had a forced expiratory volume in 1 s of 1.13 0.49 L, and a 6MWD of
305 66 m (mean SD). The CPET (nZ 24) showed a: maximum workload of 52 25 W, a peak
O2 uptake of 13.8 4.4 mL/kg/min, a peak heart rate of 127  22 bpm, a peak respiratory
exchange ratio 1.06 0.11, a ventilation (VE)/CO2 production slope of 37 11, and a peak
O2 pulse 7.5 2.3 mL. The peak VE was 41 15 L/min, and the calculated maximum voluntary
VE 45 20 L/min. There was no difference in any of the CPET variables and 6MWD between the
patients with a mPAP < 30 mm Hg (mPAP 22  6 mm Hg, nZ 15) and those with
a mPAP> 30 mm Hg (mPAP 38  6 mm Hg, nZ 14). There was no correlation between PAP
and any of the exercise measurements. These results suggest that exercise capacity in unse-
lected patients with advanced COPD and mild to moderate pulmonary hypertension is essen-
tially limited by exhaustion of the ventilatory reserve.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Pulmonary hypertension is a common complication of
advanced chronic obstructive pulmonary disease (COPD).1,2of Pathophysiology, CP 604,
e Bruxelles, 808 Lennik road,
553322; fax: þ322 555 4124.
(R. Naeije).
9 Elsevier Ltd. All rights reservedIncreased pulmonary artery pressure (PAP) in these patients
is a cause of ‘‘cor pulmonale’’ traditionally defined by an
alteration in structure and function of the right ventricle
secondary to lung disease.1,2 Pulmonary hypertension in
COPD is associated with a decreased survival rate in
proportion to increased PAP3,4 even in patients on long term
oxygen therapy.5
Exercise capacity is markedly reduced in COPD, in
proportion to severity of the disease as assessed by the
Global Initiative for Chronic Obstructive Lung Disease.
122 C. Pynnaert et al.(GOLD) staging system.6 Both peak O2 uptake (VO2) and
the distance walked in 6 min (6MWD) have been repor-
ted to be predictors of survival in COPD.7 Decreased
exercise capacity in these patients is multifactorial, due
to combined effects of dynamic hyperinflation,
decreased ventilatory reserve, and respiratory and
peripheral muscle dysfunctions.8e11 A limitation in the
cardiac output and stroke volume responses could also
play a role,12 in relation to right ventricle failure to
increase ejection fraction in the face of increased
afterload.13 A combined right heart catheterisation and
magnetic resonance imaging study recently confirmed
that stroke volume fails to increase in exercising COPD
patients, in proportion to severity of resting pulmonary
hypertension.14
We therefore hypothesized that pulmonary hypertension
participates to the limitation of exercise capacity in COPD
patients, and that this could be shown non-invasively by
a correlation between cardiopulmonary exercise test
(CPET) variables and PAP estimated by echocardiography.
Methods
Patients
We reviewed the records of consecutive patients with
stable COPD in whom lung function tests, a 6-min walk
test, a CPET, and an echocardiography had been per-
formed within the same week. All the patients gave an
informed written consent to the study, which was
approved by the Institutional Review Board of the Erasme
University Hospital. There were 19 men and 10 women,
aged 63 10 years (mean SD). The diagnosis of COPD
rested on a history of cigarette smoking, cough and
sputum production, and demonstration of irreversible
airflow obstruction, following the guidelines of the
American Thoracic Society (ATS) and the European
Respiratory Society (ERS).15 Exclusion criteria included
a recent COPD exacerbation (within 1 month), a myocar-
dial infarction, hypertension, angina, left heart failure or
neuromuscular conditions that could interfere with the
exercise tests. The patients had optimal bronchodilator
therapy, and 10 of them were on continuous low-flow
oxygen. The patients were in stages III (nZ 16) and IV
(nZ 13) of the ATS/ERS Global Initiative for Chronic
Obstructive Lung Disease (GOLD) classification.16
Six-minute walk test
All the patients underwent a 6MWD test following the ATS
guidelines.17 The patients were instructed to walk back
and forth at their own pace in a 35 m corridor to cover as
much ground possible in the allotted time. A physio-
therapist supervised the test, telling the patient the
remaining exercise time every 2 min. The patients were
allowed to stop and take a rest during the test, but were
instructed to resume walking as soon as possible. To
control for the learning effect, each patient needed to
have had at least one previous test on a separate day.
Dyspnea during the test was evaluated with the modified
Borg dyspnea score.18Cardiopulmonary exercise testing
Each patient underwent a physician-supervised standard
incremental cycle ergometer CPET until the symptom-
limited maximum.19 The work rate was increased by 5 or
10 W per min, after 1 min pedalling at 0 W, for an average
duration of CPET of approximately 10 min. The patients
were instructed to stop exercising immediately if they felt
dizziness or chest pain. Breath-by-breath ventilation, O2
and CO2 concentrations, and derived minute ventilation,
VO2 and VCO2 were determined using the Cardiopulmonary
Exercise System ‘‘CPX/D’’ (Medical Graphics, St Paul, MN).
Heart rate was measured using a continuously monitored
electrocardiogram. Blood pressure was measured at the
end of each workload increment using an automatic
sphygmomanometer. Pulse oximetric saturation (SpO2) was
measured using a Nonin 8500 M device (Nonin Medical,
Minneapolis, MN). Peak VO2 was defined as the VO2
measured during the last 30 s of peak exercise. Oxygen
pulse was calculated by dividing VO2 by heart rate. The
anaerobic threshold was detected using the V-slope
method.19 Maximum voluntary ventilation (MVV) was esti-
mated from the forced expiratory volume in 1 s (FEV1) by
the equation: FEV1 40 L/min.
Echocardiography
Echocardiography was performed with a Vivid 7 ultrasound
system (GE Ultrasound, Norway). Mean PAP (mPAP) was
calculated from the pulsed Doppler pulmonary artery flow
acceleration time, using the following equation:
mPAPZ 79e0.45 (AT), where AT mean the acceleration
time of pulmonary flow.20 Systolic PAP (sPAP) was estimated
from a trans-tricuspid gradient calculated from the
maximum velocity of continuous Doppler tricuspid regurgi-
tation (TR), with 5 mm Hg assigned to right atrial pressure,
using the equation: sPAPZ TR2 4þ 5 mm Hg.21 Mean PAP
was calculated as 0.6 sPAPþ 2.22
Pulmonary function tests
Standard pulmonary function tests were performed
according to actualised American Thoracic Society/Euro-
pean Respiratory Society guidelines23 and previously
reported European predictive values.24
Statistics
Results are presented as mean SD. The statistical analysis
consisted in unpaired Student’s t tests and correlation
calculations.25
Results
The patients had a FEV1 of 1.13 0.49 L (40% predicted,
range 31e50%), corresponding to GOLD stages III and IV.
The MVV was estimated at 45 20 L/min (limits of normal:
81e203 L/min). The arterial blood gas analysis showed a pH
of 7.42 0.05, an arterial PO2 (PaO2) of 71 13 mm Hg and
PaCO2 of 39 6 mm Hg. The echocardiography showed an
Table 2 Comparison of 6-min walk distance (6MWD),
cardio-respiratory exercise test (CPET) variables and
maximum voluntary ventilation (MVV) between COPD
patients with mean pulmonary artery pressure (mPAP)
below 30 mm Hg (nZ 15, 9 men and 6 women) or above
30 mm Hg (nZ 14, 10 men and 4 women).
Variables mPAP< 30 mm Hg mPAP> 30 mm Hg P
6MWD, m 318 89 293 110 NS
Peak work
rate, W
50 37 54 42 NS
Peak VO2,
ml/kg/min
14.4 4.2 13.7 3.8 NS
Peak O2 pulse,
ml/beat
6.8 1.7 7.9 2.1 NS
Peak RER 1.03 0.16 1.09 0.22 NS
Peak VE, L/min 40 22 42 17 NS
VE/VCO2 slope 38 18 35 17 NS
Peak HR,
beats/min
129 33 126 33 NS
MVV, L/min 48 23 42 15 NS
Peak SpO2, % 93 3 94 3 NS
For abbreviations: see Table 1.
CPET measurements were obtained in 13 patients with
a mPAP< 30 mm Hg and 11 patients with a mPAP> 30 mm Hg.
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blood flow of 30 10 mm Hg. Fourteen of the 29 patients
had a mPAP above this value, at 38 6 mm Hg, while the
mPAP was at 22 5 mm Hg in other patients. A sufficient
quality TR for the estimation of sPAP could be obtained
in 18 patients. It allowed for the calculation of a mPAP
of 31 7 mm Hg, not significantly different from a mPAP of
28 8 mm Hg calculated from the acceleration time of
pulmonary flow in the same patients.
The 6-min walk test
The patients walked 305 110 m, with an increase in heart
rate from 96 11 to 119 18 beats/min and a SpO2
decreased from 93 5 to 90 5%. The Borg dyspnea score
reached 6.4 1.2.
The cardiopulmonary exercise test
The CPET variables, which were obtained in only 24 of the
patients, are shown in Table 1. The patients presented with
marked decreases in peak VO2, workload, peak VE and peak
heart rate. The VE/VCO2 slope was moderately increased.
The maximum RER was below 1.1, suggesting sub-maximum
test. On the other hand, peak VE, was close to the esti-
mated MVV, with a mean difference of only 4 L/min, sug-
gesting ventilatory limitation.
Comparisons between COPD with and without
a mPAP> 30 mm Hg
The comparison of CPET and 6MWD of the COPD patients
with a mPAP below and above 30 mm Hg is shown in Table 2.
There was no difference in any of the exercise test vari-
ables between the two groups of patients. There was no
difference in resting arterial blood gases, resting SpO2 or
peak exercise SpO2 between the two groups of patients.
There were no correlations between mPAP and respec-
tively peak VO2 or 6MWD (Figs. 1 and 2).
There were no correlations either between mPAP, peak
VO2 and 6MWD and resting arterial blood gases, resting SpO2
or peak exercise SpO2.Table 1 Cardiopulmonary exercise test variables in 29
COPD patients.




Peak VO2, ml/kg/min 13.8 4.4 23e32
Peak O2 pulse, ml/beat 7.5 2.3 9.1e16.5
Peak RER 1.06 0.11 1.15e1.25
Peak VE, L/min 41 15 70e108
VE/VCO2 slope 37.1 12.2 33e35
Peak HR, beats/min 127 22 150e178
Peak SpO2, % 94 3 95e100
RER: respiratory exchange ratio; VO2: oxygen uptake;
VE: ventilation; VCO2: carbon dioxide output; HR: heart rate;
SpO2: pulse oximetry oxygen saturation. Limits of normal are
from Ref. 19.Discussion
The present results shown that mild to moderate pulmonary
hypertension in patients with advanced COPD does not
affect exercise capacity, which appears to be essentially
determined by an early exhaustion of the ventilatory
reserve.
The exercise test profile in the present COPD patients
populationwas characterized bymarked decreases in 6MWD,
peak VO2, and maximum workload, with a RER on average
below the cut-off of 1.15 required for the diagnosis of a peak
or maximum exercise test. The ventilatory reserve was
markedly lowered. This is typical of advanced COPD19 inFigure 1 Peak oxygen uptake (VO2) plotted against resting
mean pulmonary artery pressure (mPAP) in patients with
advanced COPD, 11 with a mPAP> 30 mm Hg, 13 with
a mPAP< 30 mm Hg. There was no correlation between peak
VO2 and mPAP. Empty circles: mPAP> 30 mm Hg.
Figure 2 Six-minute walk distance plotted against resting
mean pulmonary artery pressure (mPAP) in patients with
advanced COPD, 14 with a mPAP> 30 mm Hg, 15 with
a mPAP< 30 mm Hg. There was no correlation between peak
VO2 and mPAP. Empty circles: mPAP> 30 mm Hg.
124 C. Pynnaert et al.keeping with previously reported studies.8,9 The ventilatory
reserve in normal subjects normally amounts to anaverageof
38 L/min, whether MVV is directly measured or estimated
from a FEV1.
19 A value of less than 11 L/min is strongly
suggestive of a ventilatory limitation to exercise capacity.19
It is of interest that the ventilatory reserve in the present
series of COPD patients appeared to be more decreased in
the patients with the higher PAP, suggesting more advanced
disease, but the difference did not reach significance.
Decreased exercise capacity in COPD is multifactorial.
Increased airway resistance and lung compliance cause
a dynamic hyperinflation, which, together with respiratory
muscle fatigue, decreases the ventilatory reserve.8,10
Several studies have also reported a peripheral skeletal
muscle dysfunction,9 but whether this adds to the decrease
in ventilatory reserve to limit exercise capacity is not
entirely clear.11
Isolated pulmonary hypertension, like in pulmonary
arterial hypertension, is associated with a decreased
6MWD, and a CPET showing decreased peak VO2, workload
and pulse pressure, early lactic acidosis, increased venti-
latory equivalents but preserved ventilatory reserve, and
impaired chronotropic response.26 This is similar to the
exercise test profile characteristic in congestive heart
failure.27 We therefore reasoned that some of these char-
acteristics would be identifiable in COPD patients with
increased PAP. This was not the case in the present study,
except a marked decrease in maximum O2 pulse suggesting
a decrease in maximum stroke volume. A combined invasive
hemodynamic and magnetic resonance imaging study in
COPD patients exercised to 40% of maximum workload
showed a limitation in the increase in stroke volume and no
decrease in end-systolic right ventricular volume as
compared to controls, and this was related to resting PAP.14
Another invasive study from the same authors, performed
on a small group of 25 COPD patients, of whom 10 pre-
sented with increased PAP (to 33 7 mm Hg), showed that
the only CPET differences related to the presence of
pulmonary hypertension were an increase in ventilatory
equivalents for CO2, and a decreased SpO2.
28 However,sildenafil treatment during 3 months in 15 COPD patients
with moderate pulmonary hypertension (mPAP 22 9 mm
Hg at rest and 32 11 mm Hg at exercise) did not restore
stroke volume or exercise capacity.29 The present results
are in keep with the notion that mild to moderate pulmo-
nary hypertension does not add to ventilatory limitation (or
peripheral skeletal muscle dysfunction) to limit aerobic
exercise capacity.
The present data confirm that COPD patients at exercise
present with a markedly decreased O2 pulse, indicating
a limitation in the increased in stroke volume.30 This could
be explained by a decreased right ventricular output
because of increased PVR.14 However, as already
mentioned, the CPET profile in COPD is not suggestive of
a cardiac limitation. The slope of the VO2eQ relationship in
COPD is not different from controls, but interrupted at
a lower maximum VO2.
31 Furthermore, decreasing PVR with
sildenafil therapy does not increase stroke volume in
exercising COPD.29 A recent study reported that O2 pulse
was decreased in exercising COPD patients in proportion to
increased inspiratory to total lung capacity ratio, suggest-
ing cardiac depression caused by direct mechanical
compression by hyperinflated lungs.32 Still, it remains
difficult to understand why this cardiopulmonary interac-
tion would not be cause of earlier anaerobic threshold and
higher respiratory exchange ratio at peak levels of exercise.
The predominant limiting effect of dynamic hyperinflation
on exercise capacity in COPD is more probably decreased
maximum ventilation.
Pulmonary artery pressure in the present study was
estimated from Doppler measurements of the acceleration
time of pulmonary flow20 and the velocity of tricuspid
regurgitation.21 Both methods have been shown to be
reasonably well correlated to invasively measured mean
and systolic PAP respectively.33 However, sufficient quality
tricuspid regurgitant jets for the estimation of sPAP are
recovered in less than half of COPD patients, and their
predictive value is poor.34,35 Good quality pulmonary flow
waves can be recovered in most COPD patients, with
a satisfactory correlation to invasively measured PAP
(rZ 0.7) and an acceptable 84% positive predictive value
for pulmonary hypertension.35 Mean PAP measured from
the acceleration time of pulmonary flow has been shown to
be tightly correlated to the invasive measurement of PAP in
chronically hypoxic high altitude inhabitants.36 We there-
fore believe that the accelerations’ times of pulmonary
flow in the present study allowed for a satisfactory
assessment of the presence and severity of pulmonary
hypertension.
Most recently, Sims et al. reported an inverse correlation
between mPAP and the 6MWD demonstrated by multivar-
iate analysis in 362 patients with COPD who underwent
a right heart catheterisation at evaluation for lung trans-
plantation, with e 11 m for every 5 mm Hg increase in
mPAP, PZ 0.04.37 A similar but non-significant tendency
was noted in the present study. Borderline significance on
a much larger patient population would argue against
a strong impact of PAP on exercise capacity in any indi-
vidual patient.
Lack of invasive hemodynamic measurements and small
sample sizes are important limitations to this study. However,
right heart catheterisations are not anymore recommended
Exercise capacity and pulmonary hypertension in COPD 125in the evaluation of COPD patients, and few patients with
advanced forms of the disease have both interpretable
echocardiographic and CPET measurements. It is therefore
unlikely that larger patients’ populations will easily be
investigated for a more accurate quantification of the effects
of pulmonary hypertension on aerobic exercise capacity.
In conclusion, exercise capacity in COPD is essentially
limited by a decreased ventilatory reserve. Whether
pulmonary hypertension might limit exercise capacity in
particular and uncommon subgroups of patients with more
severe pulmonary hypertension (mPAP> 40 mm Hg) and
more moderate impairment of lung mechanics, so-called
‘‘out of proportion’’ pulmonary hypertension,4 remains to
be investigated.
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